New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 5, 2012
16:04 EDTVRX, MRXValeant and Galderma agree on revised agreement terms
Valeant Pharmaceuticals (VRX) announced that the company has reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms of the revised agreement, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and conditions Galderma currently supplies those products to Medicis Pharmaceutical Corporation (MRX). In addition, Valeant will make an upfront payment and a royalty to Galderma on sales of Sculptra. Among other things, the agreement provides for resolution of all claims asserted in Galderma's pending litigation relating to Valeant's acquisition of Medicis. In addition, Valeant will obtain North American rights to Emervel, a next generation family of hyaluronic acid dermal fillers that are specifically designed to provide both patient tolerability and long-lasting correction of facial lines, contouring and volume loss or lip enhancement. The terms of the agreement are subject to the closing of Valeant's pending acquisition of Medicis, which is expected to occur on December 11.
News For VRX;MRX From The Last 14 Days
Check below for free stories on VRX;MRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 21, 2014
07:15 EDTVRXValeant Allergan contacts Quebec, U.S. regulators regarding Allergan statements
Valeant (VRX) has contacted both the Autorite des marches financiers in Quebec and the SEC regarding Allergan (AGN) apparent attempt to "mislead investors and manipulate the market for Valeant common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information." The latest statements were made last Friday when Allergan asserted in an SEC filing that Bausch + Lomb's pharmaceutical sales were stagnant or declining. Valeant's decision to contact the authorities also reflects concerns raised by several Canadian Valeant shareholders about comments made about Valeant by Allergan's management during recent meetings with these investors in Canada.
07:09 EDTVRXValeant, Ackman go to SEC over Allergan claims, CNBC reports
Subscribe for More Information
06:34 EDTVRXCapital Research sells nearly all its Allergan stake, WSJ reports
Subscribe for More Information
July 18, 2014
12:51 EDTVRXKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
11:27 EDTVRXSamlyn undecided on support for Valeant bid for Allergan, Dow says
Subscribe for More Information
July 17, 2014
16:45 EDTVRXPershing Square looks to obtain consents for special meeting
Subscribe for More Information
08:08 EDTVRXValeant receives FDA clearance for Victus Femtosecond Laser Platform
Subscribe for More Information
07:00 EDTVRXPaulson says Allergan could be wroth $220 per share, WSJ reports
Subscribe for More Information
July 16, 2014
17:46 EDTVRXAckman says he thinks Allergan-Valeant deal eventually gets done
Subscribe for More Information
17:42 EDTVRXPershing Square's Ackman says Allergan's attack on Valeant unprecedented
Subscribe for More Information
10:36 EDTVRXTreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:16 EDTVRXPershing Square sends letter to Allergan's board of directors
Pershing Square Capital Management announced it has sent a letter to Allergan's Board of Directors. Pershing Square last Friday filed definitive solicitation materials with the U.S. SEC to seek shareholder support for a special meeting of Allergan shareholders and is now actively soliciting shareholder support to call the meeting. At this special meeting, Allergan shareholders will be able to voice their opinions on a number of critical matters, including the proposed removal of six incumbent members of the Allergan board, the proposed appointment of an independent slate of directors and certain other proposed provisions to improve Allergan’s corporate governance.
08:16 EDTVRXLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
07:59 EDTVRXTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 14, 2014
12:47 EDTVRXAllergan slides question Valeant growth, disclosures, says BMO Capital
Subscribe for More Information
08:13 EDTVRXAllergan reiterates belief that Valeant model unsustainable in new presentation
Subscribe for More Information
08:02 EDTVRXValeant submits HSR filing for proposed acquisition of Allergan
Subscribe for More Information
July 11, 2014
16:48 EDTVRXAllergan comments on Pershing Square’s definitive proxy solicitation
Allergan (AGN) provided the following comment in response to the definitive proxy solicitation filed by Pershing Square Capital Management in connection with Pershing Square’s request to call a Special Meeting of Stockholders. At the Special Meeting, if called, Allergan stockholders would be asked to remove a majority of the company’s existing directors in connection with Valeant Pharmaceuticals' (VRX) unsolicited exchange offer to acquire all outstanding common shares of Allergan for 0.83 shares of Valeant common stock and $72.00 in cash, or subject to proration, an amount of cash or a number of Valeant common shares with the implied value set forth in the exchange offer. Under the current Board’s leadership, which includes individuals with significantly more industry experience than Pershing Square’s recommended nominees, Allergan continues to execute on its plan to drive near- and long-term organic growth, enhance its growth prospects and continue generating significant value for all of Allergan’s stockholders. We believe Pershing Square’s attempt to replace a majority of the Allergan Board is a further effort to support Valeant in its bid to acquire Allergan at a grossly inadequate price that substantially undervalues the company and creates significant risks and uncertainties for Allergan stockholders. Valeant has repeatedly failed to address the serious concerns raised by Allergan and important members of the investment community about Valeant’s anemic organic growth driven by unsustainable price increases, among other fundamental business model issues. Allergan has a track record of consistently acting in the best interests of its stockholders and the Board remains confident in the company’s ability to create significantly more value than Valeant’s proposal.
July 10, 2014
09:31 EDTVRXNestle acquires rights to aesthetic dermatology products in the U.S. and Canada
Subscribe for More Information
09:31 EDTVRXValeant completes filler, toxin asset sale to Galderma
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use